The clinical study of combined chemotherapy with vinorelbine plus platinum drugs in patients aged ≥70 years and with advanced non-small cell lung cancer
10.3760/cma.j.issn.0254-9026.2009.03.007
- VernacularTitle:长春瑞滨与铂类联合治疗70岁以上老年人非小细胞肺癌的临床观察
- Author:
Qiyi MENG
;
Zhe LIU
;
Lili GUO
;
Liyan XU
;
Yunzhong ZHU
;
Heling SHI
;
Junfang TANG
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Antineoplastic combined chemotherapy protocols;
Vinca alkaloids;
Cisplatin
- From:
Chinese Journal of Geriatrics
2009;28(3):196-198
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigated the efficacy and toxic effects of combined chemotherapy of vinorelbine plus cisplatin or carboplatin in patients aged ≥ 70 years and with non-small cell lung cancer (NSCLC).Methods One hundred patients with lung cancer aged ≥70 years were enrolled in the study.Fifty patients in chemotherapy group were assigned to receive vinorelbine 25 mg/m2 at the first day and the fifth day plus cisplatin 60-70 mg/m2 or carboplatin 250 mg/m2 at the second day.All treatments were repeated every 3 or 4 weeks.Another fifty patients aged ≥ 70 years were taken as control group, not receiving treatment.The primary endpoint was survival.Results Forty-five patients were evaluable for response and the partial remission rate was 35.6% (16/45).One year survival rate was 37.8% and median survival time was 9.75 months in chemotherapy group.The median survival time was 4.0 months for patients in control group.All 50 patients in chemotherapy group were evaluable for toxic side effects.WHO grade Ⅲ incidences of leucopoenia, neutropenia and anemia were 38.0%, 52.0% and 2.2%, respectively.Grade IV incidence of neutropenia was 35.5%.WHO grade Ⅲ incidences of fatigue, constipation and vomit were 22.0%, 8.0% and 14.8%,respectively.Five patients failed to complete the treatment due to side effects.Conclusions Combined chemotherapy of vinorelbine plus platinum drugs is effective and tolerated in patients aged over 70 years with advanced NSCLC.Even patients with stable clinical effects shows benefit of survival time.
